Product image of Lenalidomide Olainfarm (Lenalidomide) supplied by GNH India

Lenalidomide Olainfarm

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomide Olainfarm (Lenalidomide)

Lenalidomide, the active ingredient in Lenalidomide Olainfarm, is an Immunomodulatory drug (IMiD) presented as a tablet for oral use. It is indicated for certain blood cancers and is administered under medical supervision.

GNH India supplies Lenalidomide Olainfarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Jsc Olainfarm

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic marrow.

  • Multiple myeloma: improves progression‑free survival and overall response rates.
  • Myelodysplastic syndromes with del(5q): reduces transfusion dependence and cytopenias.
  • Mantle cell lymphoma: contributes to disease control when combined with other agents.

How It Works

  • Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, promoting ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos. This modulates cytokine production, enhances T‑cell and NK‑cell activity, inhibits angiogenesis, and directly induces apoptosis in malignant cells.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

  • Fatigue: persistent tiredness reported by many patients.
  • Diarrhea: mild to moderate loose stools.
  • Rash: skin erythema or pruritus.
  • Nausea: occasional upset stomach.
  • Constipation: reduced bowel movements.
  • Peripheral edema: swelling of extremities.

Serious or Rare Side Effects

  • Thromboembolic events: deep vein thrombosis or pulmonary embolism.
  • Severe neutropenia: markedly low neutrophil counts increasing infection risk.
  • Hepatotoxicity: elevated liver enzymes or liver injury.
  • Secondary malignancies: emergence of new cancers.
  • Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Cardiac arrhythmias: irregular heart rhythms in susceptible individuals.

Precautions & Warnings

Patients should be monitored for known risks and contraindications before and during therapy.

  • Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception.
  • Thrombosis prophylaxis: assess need for anticoagulation in high‑risk patients.
  • Renal function: adjust monitoring if creatinine clearance is reduced.
  • Hepatic impairment: evaluate liver function tests regularly.
  • Drug interactions: review concomitant medications for potential interactions.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Avoid Interactions

Lenalidomide may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers: may reduce lenalidomide exposure.
  • Anticoagulants (e.g., warfarin): increased risk of bleeding.
  • Immunosuppressants: heightened infection risk.

Moderate Interactions (Monitor Closely)

  • CYP450 substrates metabolized by CYP2C19: possible altered plasma levels.
  • NSAIDs: may exacerbate renal toxicity.
  • Vaccines: live vaccines should be avoided during treatment.

Frequently Asked Questions

Lenalidomide Olainfarm is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with a deletion of chromosome 5q, and mantle cell lymphoma. In each case it is used as part of a prescribed therapeutic regimen to control disease progression and improve patient outcomes.

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex, leading to the degradation of transcription factors Ikaros and Aiolos. This action modulates the immune system, inhibits new blood‑vessel formation, and directly triggers apoptosis of malignant cells.

The specific dose of Lenalidomide Olainfarm is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and other individual factors. Only a qualified healthcare professional can set the appropriate dosing schedule.

Lenalidomide Olainfarm is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. Women of childbearing potential must use effective contraception, and breastfeeding is not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug class, offering both direct anti‑tumor activity and immune‑enhancing effects. Compared with proteasome inhibitors or monoclonal antibodies, lenalidomide provides an oral administration route and a distinct mechanism, often used in combination regimens to achieve synergistic benefits.

Lenalidomide Olainfarm should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed when not in use.

Lenalidomide Olainfarm is taken orally, usually as a tablet, with or without food as directed by the prescribing physician. The exact schedule—such as daily dosing or specific cycle days—will be outlined in the treatment plan.

Serious risks include thromboembolic events (blood clots), severe neutropenia leading to infection, hepatotoxicity, secondary malignancies, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for these events throughout therapy.

Lenalidomide Olainfarm should not be used by individuals who are pregnant, have uncontrolled infections, have a known hypersensitivity to lenalidomide or any excipients, or have severe renal or hepatic impairment without appropriate medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT